EIF2A and glioblastoma: Finally, similar to raphin-1 and salubrinal, the S51D phosphomimetic eIF2α variant increases the sensitivity of PED-GBM to niraparib, ascertaining the role of P-eIF2α in modulating the PED-GBM response to PARPis.